We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00420082
Recruitment Status : Completed
First Posted : January 9, 2007
Last Update Posted : April 5, 2012
Information provided by (Responsible Party):
Faes Farma, S.A.

Brief Summary:
This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.

Condition or disease Intervention/treatment Phase
Seasonal Allergic Rhinitis Drug: Bilastine Drug: Fexofenadine Drug: Cetirizine Drug: Placebo Phase 2

Detailed Description:
The objective of the study is to determine the effect of a single dose of bilastine 20 mg on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber . This effect will be compared to that action of Cetirizine 10 mg, Fexofenadine 120 mg, and placebo. To explore the onset of action, patients will receive study drug two hours after the start of the provocation on Day 1.Patients will remain in theVCC for an additional four hours. On Day 2, patients will return to the VCC post-dose hours 22-26.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber
Study Start Date : October 2006
Actual Study Completion Date : December 2006

Arm Intervention/treatment
Experimental: 1
Bilastine 20 mg
Drug: Bilastine
Encapsulated Bilastine 20 mg tablets Q.D.

Active Comparator: 2
Fexofenadine 120 mg
Drug: Fexofenadine
Encapsulated Fexofenadine 120 mg tablets Q.D.
Other Name: Allegra

Active Comparator: 3
Cetirizine 10 mg
Drug: Cetirizine
Encapsulated Cetirizine 10 mg tablets Q.D.
Other Name: Zyrtec

Placebo Comparator: 4
Drug: Placebo
Encapsulated Placebo tablets Q.D.

Primary Outcome Measures :
  1. Onset of action and action duration

Secondary Outcome Measures :
  1. Nasal and ocular symptom scores
  2. Nasal airflow resistance
  3. Nasal secretion weight
  4. FEV1
  5. Routine safety parameters (vital signs, ECGs, clinical laboratory tests)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a history of seasonal allergic rhinitis
  • Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit

Exclusion Criteria:

  • Have a clinically significant illness or disease
  • Have unstable asthma
  • Has participated in a clinical trial 30 days prior to the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00420082

Layout table for location information
Allergy Center Vienna West
Vienna, Austria, A-1150
Sponsors and Collaborators
Faes Farma, S.A.
Layout table for investigator information
Principal Investigator: Friedrich Horak, Professor ENT University Clinic Vienna
Publications of Results:
Layout table for additonal information
Responsible Party: Faes Farma, S.A.
ClinicalTrials.gov Identifier: NCT00420082    
Other Study ID Numbers: BILA-2306/ACC
2006-003004-19 ( EudraCT Number )
First Posted: January 9, 2007    Key Record Dates
Last Update Posted: April 5, 2012
Last Verified: April 2012
Keywords provided by Faes Farma, S.A.:
Pollen allergy
Environmental Exposure Chamber
Challenge Chamber
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Respiratory Tract Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs